The gastroparesis treatment market comprises products used to manage and treat gastroparesis. Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis often occurs due to diabetes, surgery, or idiopathic causes. Common symptoms include nausea, vomiting, appetite loss, and bloating. Treatment options include prokinetic drugs that aid gastric emptying, antiemetics to reduce nausea and vomiting, and nutritional and dietary modifications.  

Global gastroparesis treatment market is estimated to be valued at USD 7.95 Bn in 2024 and is expected to reach USD 10.91 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 4.6% from 2024 to 2031. 

Key players operating in the gastroparesis treatment are Evoke Pharma, Inc., Processa 

Pharmaceuticals, Inc., Neurogastrx, Inc., Vanda Pharmaceuticals Inc., ANI Pharmaceuticals, 

Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Otsuka Holdings Co., 

Ltd., CinDome Pharma, Inc., PTC Therapeutics, Pfizer, Inc., Teva Pharmaceutical Industries 

Ltd., Atlantic Healthcare, Salix Pharmaceuticals, Rhythm Pharmaceuticals, Inc., Ironwood Pharmaceuticals, Inc., Medtronic plc, Bausch Health Companies Inc., Sanofi S.A. 

The Gastroparesis Treatment Market share is also expanding globally due to rising awareness regarding gastroparesis disorders and increasing healthcare expenditure. For instance, many developing countries are witnessing rising incidences of gastroparesis due to lifestyle changes and diet patterns.

The gastroparesis treatment market is also expanding globally due to rising awareness regarding gastroparesis disorders and increasing healthcare expenditure. For instance, many developing countries are witnessing rising incidences of gastroparesis due to lifestyle changes and diet patterns. 

This is boosting the demand for improved diagnosis and treatment of gastroparesis. Moreover, large players are focusing on new product launches to expand their presence in high-growth markets. For example, in September 2020, Evoke Pharma launched Gimoti nasal spray for relief of symptoms in adult women with diabetes mellitus-induced gastroparesis. 

The key trend gaining traction in the gastroparesis treatment market is the increasing research activities focused on gut-brain axis disorders. Gastroparesis has strong associations with neurological disorders. Researchers are investigating molecular mechanisms linking the enteric nervous system and the brain. Understanding the connections between the gut and the brain can help develop more effective treatments for refractory gastroparesis. Companies are also exploring new therapeutic targets such as microRNAs and neurotransmitters in the gutbrain axis to manage gastroparesis symptoms. This focus on gut-brain axis is expected to open avenues for advancements in gastroparesis treatment over the forecast period. 

Porter’s Analysis 

Threat of new entrants: There is a moderate threat of new entrants in the gastroparesis treatment market due to the requirement of various clinical trials and approvals from regulatory authorities like FDA.  

Bargaining power of buyers: The bargaining power of buyers is moderate owing to the availability of limited treatment options for gastroparesis.  

Bargaining power of suppliers: The bargaining power of suppliers is low since there are numerous drug manufacturers and suppliers present in this market. 

Threat of new substitutes: There is low threat of new substitutes due to limited availability of alternative treatment modalities for gastroparesis. 

Competitive rivalry: The competitive rivalry is high owing to the presence of many established players in the gastroparesis treatment market. 

Geographical Regions 

The Gastroparesis Treatment Market Regions Analysis indicates that, in terms of value, the North America region is concentrated for the gastroparesis treatment market mainly due to the growing prevalence of gastroparesis, increasing diabetes population, and availability of advanced healthcare facilities. 

Asia Pacific is considered as the fastest growing region for the gastroparesis treatment market over the forecast period owing to growing cases of diabetes and improving healthcare infrastructure in emerging countries like China and India. 

 Select the language you're most comfortable with.

•    Japanese

•    Korean

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.

(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)